Devika Bose

Ms. Devika Bose

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
RSRuchi Sharma
Ruchi Sharma
Devika BoseDevika Bose
Devika Bose
AMArvydas Maminishkis
Arvydas Maminishkis
KBKapil Bharti
Kapil Bharti
Pluripotent stem cells (PSCs) are a potential replacement tissue source for degenerative diseases. Age-related macular degeneration (AMD) is a blinding disease triggered by degeneration of the retinal pigment epithelium (RPE), a monolayer tissue that functionally supports retinal photoreceptors. Recently published clinical and preclinical studies have tested PSC-derived RPE as a potential treatment for AMD. Multiple approaches have been used to manufacture RPE cells, to validate them functionally, to confirm their safety profile, and to deliver them to patients either as suspension or as a monolayer patch. Since most of these studies are at an early regulatory approval stage, the primary outcome has been to determine the safety of RPE transplants in patients. However, preliminary signs of efficacy were observed in a few patients. Here, we review the current progress in the PSC-derived RPE transplantation field and provide a comparative assessment of various approaches under development as potential therapeutics for AMD.

22 December 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MSMin Jae Song
Min Jae Song
RQRuss Quinn
Russ Quinn
ENEric Nguyen
Eric Nguyen
CHChristopher Hampton
Christopher Hampton
RSRuchi Sharma
Ruchi Sharma
KBKapil Bharti
Kapil Bharti

15 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RSRuchi Sharma
Ruchi Sharma
AGAman George
Aman George
MNMalika Nimmagadda
Malika Nimmagadda
DODavide Ortolan
Davide Ortolan
BKBarbosa-Sabanero Karla
Barbosa-Sabanero Karla
KBKapil Bharti
Kapil Bharti
Age-related Macular Degeneration (AMD), a blinding eye disease, is characterized by pathological protein- and lipid-rich drusen deposits underneath the retinal pigment epithelium (RPE) and atrophy of the RPE monolayer in advanced disease stages - leading to photoreceptor cell death and vision loss. Currently, there are no drugs that stop drusen formation or RPE atrophy in AMD. Here we provide an iPSC-RPE AMD model that recapitulates drusen and RPE atrophy. Drusen deposition is dependent on AMD-risk-allele CFH(H/H) and anaphylatoxin triggered alternate complement signaling via the activation of NF-κB and downregulation of autophagy pathways. Through high-throughput screening we identify two drugs, L-745,870, a dopamine receptor antagonist, and aminocaproic acid, a protease inhibitor that reduce drusen deposits and restore RPE epithelial phenotype in anaphylatoxin challenged iPSC-RPE with or without the CFH(H/H) genotype. This comprehensive iPSC-RPE model replicates key AMD phenotypes, provides molecular insight into the role of CFH(H/H) risk-allele in AMD, and discovers two candidate drugs to treat AMD.

20 July 2022 in STAR Protocols
Verified
Journal Article
Open access
RSRuchi Sharma
Ruchi Sharma
Devika BoseDevika Bose
Devika Bose
JMJair Montford
Jair Montford
DODavide Ortolan
Davide Ortolan
KBKapil Bharti
Kapil Bharti
RPE tissues are derived from induced pluripotent stem cells (iPSCs) to model retinal diseases and as a replacement therapy for macular degeneration. Here, we developed a robust and efficient directed differentiation protocol to generate pure RPE cells that form a polarized monolayer. This protocol describes how to set up RPE differentiation and to obtain a pure population that expresses mature RPE markers and forms strong tight junctions.

27 October 2022 in Stem Cell Reports
Verified
Journal Article
Open access
MFMitra Farnoodian
Mitra Farnoodian
Devika BoseDevika Bose
Devika Bose
VKVladimir Khristov
Vladimir Khristov
Praveen Joseph SusaimanickamPraveen Joseph Susaimanickam
Praveen Joseph Susaimanickam
SMSavitri Maddileti
Savitri Maddileti
KBKapil Bharti
Kapil Bharti
Stargardt retinopathy is an inherited form of macular degeneration caused by mutations in gene ABCA4 and characterized by the accumulation of lipid-rich deposits in the retinal pigment epithelium (RPE), RPE atrophy, and photoreceptor cell death. Inadequate mechanistic insights into pathophysiological changes occurring in Stargardt RPE have hindered disease treatments. Here, we show that ABCA4 knockout and induced pluripotent stem cell-derived RPE (STGD1-iRPE) from patients with Stargardt differentiate normally but display intracellular lipid and ceramide deposits reminiscent of the disease phenotype. STGD1-iRPE also shows defective photoreceptor outer segment (POS) processing and reduced cathepsin B activity—indicating higher lysosomal pH. Lipid deposits in STGD1-iRPE are lowered by increasing the activity of ABCA1, a lipid transporter, and ABCA4 ortholog. Our work suggests that ABCA4 is involved in POS and lipid handling in RPE cells and provides guidance for ongoing gene therapy approaches to target both RPE and photoreceptor cells for an effective treatment.

9 December 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
KMKiyoharu Joshua Miyagishima
Kiyoharu Joshua Miyagishima
RSRuchi Sharma
Ruchi Sharma
MNMalika Nimmagadda
Malika Nimmagadda
KCKatharina Clore-Gronenborn
Katharina Clore-Gronenborn
ZQZoya Qureshy
Zoya Qureshy
KBKapil Bharti
Kapil Bharti
Late-onset retinal degeneration (L-ORD) is an autosomal dominant disorder caused by a missense substitution in CTRP5. Distinctive clinical features include sub-retinal pigment epithelium (RPE) deposits, choroidal neovascularization, and RPE atrophy. In induced pluripotent stem cells-derived RPE from L-ORD patients (L-ORD-iRPE), we show that the dominant pathogenic CTRP5 variant leads to reduced CTRP5 secretion. In silico modeling suggests lower binding of mutant CTRP5 to adiponectin receptor 1 (ADIPOR1). Downstream of ADIPOR1 sustained activation of AMPK renders it insensitive to changes in AMP/ATP ratio resulting in defective lipid metabolism, reduced Neuroprotectin D1(NPD1) secretion, lower mitochondrial respiration, and reduced ATP production. These metabolic defects result in accumulation of sub-RPE deposits and leave L-ORD-iRPE susceptible to dedifferentiation. Gene augmentation of L-ORD-iRPE with WT CTRP5 or modulation of AMPK, by metformin, re-sensitize L-ORD-iRPE to changes in cellular energy status alleviating the disease cellular phenotypes. Our data suggests a mechanism for the dominant behavior of CTRP5 mutation and provides potential treatment strategies for L-ORD patients.